TB

This document sets out basic principles for prioritizing risk groups and choosing a screening approach. It emphasizes the importance of assessing the epidemiological situation, adapting approaches to local situations, integrating TB screening into other health-promotion activities, minimizing the risk of harm to individuals, and engaging in continual monitoring and evaluation.

The goal of the Global Fund (to eliminate AIDS, tuberculosis, and malaria) resonates powerfully with many young people and in response to frequent questions about how they could be involved, the Fund issued a Youth Guide directed especially to their interests. Silhouette illustrations make it racially universal and allow readers to project themselves into the images.

This fact sheet provides basic information about TB.

This interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the Programmatic Management of Drug-resistant TB (2011 Update).

The Tuberculosis Drug Information Guide, 2nd edition, is derived from Drug-Resistant Tuberculosis: A Survival Guide for Clinicians (2nd edition) produced in 2008. Two additional drugs, ofloxacin and clarithromycin (which are used primarily outside of the US), have been included. This Guide can help any physician, nurse, or pharmacist who participates in the management of patients with TB or LTBI.

Based on The Union's 93-years of working in the field, the new guide tackles the challenges of fulfilling each patient's potential for cure from both the clinician's and the programme manager's perspective.

This fact sheet describes the impact of HIV-TB co-infection. It also presents work currently being done to find and treat HIV-TB.

The US Agency for International Development (USAID) has reported to Congress on its international foreign assistance efforts to control tuberculosis (TB). Titled Leading and Leveraging, the report documents work completed the previous fiscal year.

This application, created by the WMA and the New Jersey Medical School Global Tuberculosis Institute, gives physicians the flexibility to access the course material at any time, even when they are discussing treatment options with their patients. The application was developed in collaboration with the World Health Organization with financial support from the Eli Lilly MDR-TB partnership. The application contains the eight training modules which comprise the WMA's course on MDR-TB.

This document revises previous WHO standard case definitions for TB and drug-resistant TB, the categories used to assign outcomes, and the standard reporting framework for TB.